TC
ADPT icon

TwinBeech Capital’s Adaptive Biotechnologies ADPT Stock Holding History

TwinBeech Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54,277
Closed -$753K – 358
2026
Q1 		$753K Buy
+54,277
New +$865K 0.08% 302
2023
Q3 		– Sell
-50,688
Closed -$340K – 614
2023
Q2 		$340K Buy
+50,688
New +$377K 0.01% 535

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

TwinBeech Capital's ADPT Position: Q2 2026 in Review

TwinBeech Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 54,277 shares — an estimated $753K sold.

TwinBeech Capital first reported a position in ADPT in Q2 2023 and held it in 2 quarters. The position peaked at $753K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • TwinBeech Capital reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • TwinBeech Capital sold 54,277 Adaptive Biotechnologies shares in Q2 2026, an estimated $753K.
  • TwinBeech Capital first reported a position in Adaptive Biotechnologies in Q2 2023 and held it in 2 quarters.
  • TwinBeech Capital's Adaptive Biotechnologies position peaked at $753K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.